Vistagen Therapeutics (VTGN) Return on Invested Capital (2017 - 2025)
Historic Return on Invested Capital for Vistagen Therapeutics (VTGN) over the last 11 years, with Q2 2025 value amounting to 0.94%.
- Vistagen Therapeutics' Return on Invested Capital fell 5900.0% to 0.94% in Q2 2025 from the same period last year, while for Jun 2025 it was 0.94%, marking a year-over-year decrease of 5900.0%. This contributed to the annual value of 0.61% for FY2025, which is 800.0% down from last year.
- Latest data reveals that Vistagen Therapeutics reported Return on Invested Capital of 0.94% as of Q2 2025, which was down 5900.0% from 0.74% recorded in Q1 2025.
- Over the past 5 years, Vistagen Therapeutics' Return on Invested Capital peaked at 0.19% during Q1 2021, and registered a low of 4.91% during Q2 2023.
- Its 5-year average for Return on Invested Capital is 1.18%, with a median of 0.63% in 2022.
- Per our database at Business Quant, Vistagen Therapeutics' Return on Invested Capital crashed by -229100bps in 2021 and then soared by 45600bps in 2024.
- Vistagen Therapeutics' Return on Invested Capital (Quarter) stood at 0.46% in 2021, then tumbled by -446bps to 2.53% in 2022, then soared by 83bps to 0.43% in 2023, then crashed by -42bps to 0.61% in 2024, then plummeted by -55bps to 0.94% in 2025.
- Its last three reported values are 0.94% in Q2 2025, 0.74% for Q1 2025, and 0.61% during Q4 2024.